Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy.

Ishii S, Inomata T, Ikeda Y, Nabeta T, Iwamoto M, Watanabe I, Naruke T, Shinagawa H, Koitabashi T, Nishii M, Takeuchi I, Izumi T.

Heart Vessels. 2014 Jan;29(1):88-96. doi: 10.1007/s00380-013-0335-0. Epub 2013 Mar 22.

PMID:
23519525
2.

Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy.

Ikeda Y, Inomata T, Iida Y, Iwamoto-Ishida M, Nabeta T, Ishii S, Sato T, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Nishii M, Ako J.

Heart Vessels. 2016 Apr;31(4):545-54. doi: 10.1007/s00380-015-0648-2. Epub 2015 Feb 17.

PMID:
25686768
3.

Evaluation of global circumferential strain as prognostic marker after administration of β-blockers for dilated cardiomyopathy.

Tanaka H, Matsumoto K, Sawa T, Miyoshi T, Motoji Y, Imanishi J, Mochizuki Y, Tatsumi K, Hirata K.

Int J Cardiovasc Imaging. 2014 Oct;30(7):1279-87. doi: 10.1007/s10554-014-0463-3. Epub 2014 Jun 5.

PMID:
24899221
4.

Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.

Castelli G, Fornaro A, Ciaccheri M, Dolara A, Troiani V, Tomberli B, Olivotto I, Gensini GF.

Circ Heart Fail. 2013 Sep 1;6(5):913-21. doi: 10.1161/CIRCHEARTFAILURE.112.000120. Epub 2013 Jul 25.

5.

Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy.

Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, Furuno T, Takata J, Doi YL.

Am J Cardiol. 2011 Apr 1;107(7):1065-70. doi: 10.1016/j.amjcard.2010.11.033. Epub 2011 Feb 4.

PMID:
21296328
6.

Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study.

Masci PG, Schuurman R, Andrea B, Ripoli A, Coceani M, Chiappino S, Todiere G, Srebot V, Passino C, Aquaro GD, Emdin M, Lombardi M.

Circ Cardiovasc Imaging. 2013 Sep;6(5):790-9. doi: 10.1161/CIRCIMAGING.113.000438. Epub 2013 Aug 9.

7.

Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Ponikowski P, Anker SD, Chua TP, Szelemej R, Piepoli M, Adamopoulos S, Webb-Peploe K, Harrington D, Banasiak W, Wrabec K, Coats AJ.

Am J Cardiol. 1997 Jun 15;79(12):1645-50.

PMID:
9202356
8.

T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure.

Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, Hinojar R, Doltra A, Varma N, Child N, Rogers T, Suna G, Arroyo Ucar E, Goodman B, Khan S, Dabir D, Herrmann E, Zeiher AM, Nagel E; International T1 Multicentre CMR Outcome Study.

JACC Cardiovasc Imaging. 2016 Jan;9(1):40-50. doi: 10.1016/j.jcmg.2015.12.001.

9.

Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.

Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C.

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H435-41. doi: 10.1152/ajpheart.00591.2008. Epub 2008 Dec 12.

10.

Dilated cardiomyopathy with hypertension: prevalence and response to high-dose β1-adrenoceptor antagonist therapy.

Zheng X, Chen S, Wang J, Yang T, Chen Y.

Clin Exp Pharmacol Physiol. 2009 Sep;36(9):945-9. doi: 10.1111/j.1440-1681.2009.05184.x. Epub 2009 Mar 26.

PMID:
19473337
11.

Prognostic factors and predictors of in-hospital mortality of patients with heart failure with preserved left ventricular ejection fraction.

Pérez de Isla L, Zamorano J, Hernández N, Contreras L, Rodrigo JL, Almería C, Aubele AL, Mataix L, Macaya C.

J Cardiovasc Med (Hagerstown). 2008 Oct;9(10):1011-5. doi: 10.2459/JCM.0b013e3282fbca87.

PMID:
18799963
12.

I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.

Abdel-Salam Z, Rayan M, Saleh A, Abdel-Barr MG, Hussain M, Nammas W.

Cardiol J. 2015;22(2):227-32. doi: 10.5603/CJ.a2014.0057. Epub 2014 Sep 2.

PMID:
25179314
13.
14.

Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure.

Kobayashi S, Susa T, Tanaka T, Murakami W, Fukuta S, Okuda S, Doi M, Wada Y, Nao T, Yamada J, Okamura T, Yano M, Matsuzaki M.

Circ J. 2012;76(7):1646-53. Epub 2012 Apr 5.

15.

Differences in management and outcome of ischemic and non-ischemic cardiomyopathy.

Ng AC, Sindone AP, Wong HS, Freedman SB.

Int J Cardiol. 2008 Sep 26;129(2):198-204. Epub 2007 Aug 15.

PMID:
17706807
16.
17.

Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy.

Nanas JN, Tsagalou EP, Nanas SN, Terrovitis JV, Tsolakis EJ, Toumanidis S, Papazoglou PD, Alexopoulos GP, Kanakakis J, Anastasiou-Nana MI.

Int J Cardiol. 2006 Apr 4;108(2):237-43. Epub 2005 Sep 22.

PMID:
16183152
18.

A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing-induced model of canine heart failure.

Shirasaka T, Miyagawa S, Fukushima S, Saito A, Shiozaki M, Kawaguchi N, Matsuura N, Nakatani S, Sakai Y, Daimon T, Okita Y, Sawa Y.

J Thorac Cardiovasc Surg. 2013 Aug;146(2):413-21. doi: 10.1016/j.jtcvs.2012.10.003. Epub 2013 Mar 28.

19.

Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.

Hamada M, Hara Y, Ohtsuka T, Suzuki J, Saeki H, Ogimoto A, Shigematsu Y.

J Cardiovasc Pharmacol. 2003 Jan;41 Suppl 1:S5-10.

PMID:
12688389
20.

Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy.

Badenhorst D, Norton GR, Sliwa K, Brooksbank R, Essop R, Sareli P, Woodiwiss AJ.

Pharmacogenomics J. 2007 Oct;7(5):339-45. Epub 2006 Nov 21.

PMID:
17117186

Supplemental Content

Support Center